Aug 22, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Here's Why Veracyte ( VCYT ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Aug 15, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Here's Why Veracyte ( VCYT ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Aug 12, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.
Aug 07, 2025 • Benzinga
NEUTRAL
Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care
Collaboration brings whole-exome based hereditary cancer insights to urologists and their patients by offering it alongside Veracyte's Decipher Prostate Test
Aug 07, 2025 • Motley Fool
NEUTRAL
Veracyte ( VCYT ) Q2 Revenue Jumps 14%
Veracyte ( NASDAQ:VCYT ) , a leader in advanced cancer diagnostics, reported results for Q2 2025 on August 6, 2025. The headline news: the company outperformed expectations on both revenue and profitability, driven by strong expansion in its core prostate cancer genomic testing platform.
Aug 06, 2025 • Zacks Commentary
NEUTRAL
Veracyte ( VCYT ) Tops Q2 Earnings and Revenue Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of +41.94% and +7.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?